Overnight switch from levetiracetam to brivaracetam. Safety and tolerability

Brivaracetam is a newer antiseizure medication than levetiracetam. It has a more selective action on the synaptic vesicle glycoprotein 2A binding site, and it seems to provide a more favorable neuropsychiatric profile. The aim of this study was to assess the safety and tolerability of an overnight s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	L. Abraira, J. Salas-Puig, M. Quintana, I.M. Seijo-Raposo, E. Santamarina, E. Fonseca, M. Toledo
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Brivaracetam Epilepsy Levetiracetam Safety profile Tolerability Antiseizure medication Neurology. Diseases of the nervous system RC346-429 Neurophysiology and neuropsychology QP351-495
Acceso en línea:	https://doaj.org/article/6d650cfbfe974b3c951bb5a60f53ba0b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6d650cfbfe974b3c951bb5a60f53ba0b
record_format	dspace
spelling	oai:doaj.org-article:6d650cfbfe974b3c951bb5a60f53ba0b2021-12-02T05:03:32ZOvernight switch from levetiracetam to brivaracetam. Safety and tolerability2589-986410.1016/j.ebr.2021.100504https://doaj.org/article/6d650cfbfe974b3c951bb5a60f53ba0b2021-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2589986421000782https://doaj.org/toc/2589-9864Brivaracetam is a newer antiseizure medication than levetiracetam. It has a more selective action on the synaptic vesicle glycoprotein 2A binding site, and it seems to provide a more favorable neuropsychiatric profile. The aim of this study was to assess the safety and tolerability of an overnight switch from levetiracetam to brivaracetam.This was a retrospective descriptive study including patients with epilepsy treated with levetiracetam, who switched due to inefficacy or previous adverse events (AEs). In total, forty-one patients were included (mean age 40.9 ± 17.8 years, women 48.8%). Focal epilepsy represented 75.6% (n = 31) of patients (structural cause [n = 25], unknown cause [n = 6]). Four patients had idiopathic generalized epilepsy, two had developmental and epileptic encephalopathy and four patients were unclassified. The reason to start brivaracetam was inefficacy in 53.7% (n = 22), AEs in 65.9% (25/27 neuropsychiatric) and both in 19.5% (n = 8). Brivaracetam-related AEs were reported in 24.4%. Neuropsychological AEs associated with the previous use of levetiracetam improved in 76% of patients. Treatment was discontinued in 19.5% patients. Patients’ reported seizure frequency improved, worsened and remained stable in 26.8%, 12.2%, and 61.0% of the cases, respectively.An overnight switching to brivaracetam is safe and well tolerated. This treatment can improve levetiracetam-related neuropsychiatric AEs.L. AbrairaJ. Salas-PuigM. QuintanaI.M. Seijo-RaposoE. SantamarinaE. FonsecaM. ToledoElsevierarticleBrivaracetamEpilepsyLevetiracetamSafety profileTolerabilityAntiseizure medicationNeurology. Diseases of the nervous systemRC346-429Neurophysiology and neuropsychologyQP351-495ENEpilepsy & Behavior Reports, Vol 16, Iss , Pp 100504- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Brivaracetam Epilepsy Levetiracetam Safety profile Tolerability Antiseizure medication Neurology. Diseases of the nervous system RC346-429 Neurophysiology and neuropsychology QP351-495
spellingShingle	Brivaracetam Epilepsy Levetiracetam Safety profile Tolerability Antiseizure medication Neurology. Diseases of the nervous system RC346-429 Neurophysiology and neuropsychology QP351-495 L. Abraira J. Salas-Puig M. Quintana I.M. Seijo-Raposo E. Santamarina E. Fonseca M. Toledo Overnight switch from levetiracetam to brivaracetam. Safety and tolerability
description	Brivaracetam is a newer antiseizure medication than levetiracetam. It has a more selective action on the synaptic vesicle glycoprotein 2A binding site, and it seems to provide a more favorable neuropsychiatric profile. The aim of this study was to assess the safety and tolerability of an overnight switch from levetiracetam to brivaracetam.This was a retrospective descriptive study including patients with epilepsy treated with levetiracetam, who switched due to inefficacy or previous adverse events (AEs). In total, forty-one patients were included (mean age 40.9 ± 17.8 years, women 48.8%). Focal epilepsy represented 75.6% (n = 31) of patients (structural cause [n = 25], unknown cause [n = 6]). Four patients had idiopathic generalized epilepsy, two had developmental and epileptic encephalopathy and four patients were unclassified. The reason to start brivaracetam was inefficacy in 53.7% (n = 22), AEs in 65.9% (25/27 neuropsychiatric) and both in 19.5% (n = 8). Brivaracetam-related AEs were reported in 24.4%. Neuropsychological AEs associated with the previous use of levetiracetam improved in 76% of patients. Treatment was discontinued in 19.5% patients. Patients’ reported seizure frequency improved, worsened and remained stable in 26.8%, 12.2%, and 61.0% of the cases, respectively.An overnight switching to brivaracetam is safe and well tolerated. This treatment can improve levetiracetam-related neuropsychiatric AEs.
format	article
author	L. Abraira J. Salas-Puig M. Quintana I.M. Seijo-Raposo E. Santamarina E. Fonseca M. Toledo
author_facet	L. Abraira J. Salas-Puig M. Quintana I.M. Seijo-Raposo E. Santamarina E. Fonseca M. Toledo
author_sort	L. Abraira
title	Overnight switch from levetiracetam to brivaracetam. Safety and tolerability
title_short	Overnight switch from levetiracetam to brivaracetam. Safety and tolerability
title_full	Overnight switch from levetiracetam to brivaracetam. Safety and tolerability
title_fullStr	Overnight switch from levetiracetam to brivaracetam. Safety and tolerability
title_full_unstemmed	Overnight switch from levetiracetam to brivaracetam. Safety and tolerability
title_sort	overnight switch from levetiracetam to brivaracetam. safety and tolerability
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/6d650cfbfe974b3c951bb5a60f53ba0b
work_keys_str_mv	AT labraira overnightswitchfromlevetiracetamtobrivaracetamsafetyandtolerability AT jsalaspuig overnightswitchfromlevetiracetamtobrivaracetamsafetyandtolerability AT mquintana overnightswitchfromlevetiracetamtobrivaracetamsafetyandtolerability AT imseijoraposo overnightswitchfromlevetiracetamtobrivaracetamsafetyandtolerability AT esantamarina overnightswitchfromlevetiracetamtobrivaracetamsafetyandtolerability AT efonseca overnightswitchfromlevetiracetamtobrivaracetamsafetyandtolerability AT mtoledo overnightswitchfromlevetiracetamtobrivaracetamsafetyandtolerability
_version_	1718400656507666432

Overnight switch from levetiracetam to brivaracetam. Safety and tolerability

Ejemplares similares